AIM-listed drug discovery and development firm Redx Pharma has appointed Dr Jane Robertson as Chief Medical Officer. 

Robertson, a well respected UK haemato-oncologist with over 17 years’ experience of clinical development in oncology, will commence her role at the cancer and fibrosis focused firm in March 2021.

She joins the firm form Achilles Therapeutics, a BioTech company focused on the creation of a personalized T cell therapy directed against clonal tumour neoantigens.

During her tenure at Achilles, the company progressed its lead candidate into two clinical trials.  

Prior to Achilles, Robertson served as the Chief Medical Officer at Nucana Biomed and at Kesios Therapeutics.  

She has previously also held a number of senior R&D leadership roles at AstraZeneca Oncology, notably leading the development of the first in class PARP inhibitor, olaparib.

Lisa Anson, Chief Executive Officer of Redx Pharma said: “We are absolutely delighted that Jane has chosen to join our team at this exciting stage in Redx’s development.  As our Chief Medical Officer, her extensive and varied experience in big pharma, biotech and clinical practice, will be invaluable as we further progress our pipeline into clinical development.”

Robertson added: “I have been very impressed by Redx and its outstanding scientific team, and am really looking forward to the opportunity to progress the Company’s promising pipeline into differentiated clinical stage programmes in the treatment of fibrotic diseases and cancer. With data expected from Redx’s Phase 1 RXC004 study in H1 2021, this feels like a particularly exciting time to be joining the Company.”

Following a handover, Dr Andrew Saunders will leave Redx after 3 years as Chief Medical Officer to pursue other opportunities.